跳至主要内容
临床试验/NCT03585426
NCT03585426Unknown4 期

Vancomycin in the Target Site Treatment of Intracranial Infection : a New Strategy for PK/PD Treatment

Xijing Hospital0 个研究点目标入组 2 人开始时间: 2016年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
发起方
入组人数
2
主要终点
Vancomycin concentration change in serum and cerebrospinal fluid

研究概览

简要总结

Vancomycin, a novel intravenously administered antibiotic, currently plays a key role in the management of complicated multi-organism infections. However,current LC-MS/MS methods briefly describe parameters and the only reported internal standard was sometimes difficult to obtain. In our study,an updated LC-MS/MS method for the quantitative analysis of vancomycin in human serum was developed.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Investigator)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • In ICU; ventricle drainage was carried out; renal function is normal, namely creatinine clearance rate is >60ml/min;

排除标准

  • women in pregnancy or lactation;in patients with renal insufficiency, the creatinine clearance rate (Clcr) is less than 60ml/min.

研究组 & 干预措施

Vancomycin 1g q12h

Experimental

干预措施: Vancomycin (Drug)

Vancomycin 1g q8h

Experimental

干预措施: Vancomycin (Drug)

结局指标

主要结局

Vancomycin concentration change in serum and cerebrospinal fluid

时间窗: 0.5h, 1h, 1.5h, 3h, 5h, 7h, 9h, and 12h after treatment

Quantitative analysis of vancomycin in serum and cerebrospinal fluid after treatment by an updated LC-MS/MS method.

次要结局

未报告次要终点

研究者

发起方
Xijing Hospital
申办方类型
Other
责任方
Sponsor

相似试验